Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Company Overview

Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing novel therapies for autoimmune and inflammatory diseases. Its flagship product, Lupkynis (voclosporin), is approved for the treatment of lupus nephritis, a severe kidney inflammation that arises from systemic lupus erythematosus. Aurinia’s research pipeline also encompasses investigational candidates targeting other immune‐mediated conditions, leveraging proprietary small‐molecule platform technologies to modulate key pathways involved in disease progression.

Since its founding in 1993 and its relocation of global headquarters to Victoria, British Columbia, Aurinia has expanded its operational footprint with a strategic presence in the United States and Europe. The company collaborates with contract research organizations and clinical centers worldwide to advance its studies, ensuring robust patient enrollment and regulatory engagement across major markets. Aurinia’s manufacturing partnerships support scalable production of its lead therapy, while its commercial infrastructure continues to evolve as Lupkynis reaches new patient populations.

Under the leadership of an experienced management team with deep expertise in biopharmaceutical development and commercialization, Aurinia is committed to achieving sustainable growth through disciplined clinical execution and strategic alliances. The company’s board of directors includes industry veterans from both large pharmaceutical companies and innovative biotech startups. Aurinia remains focused on delivering transformative treatments to patients with high unmet medical needs and on building long‐term shareholder value through scientific innovation and operational excellence.

Key Stats

• Today's Range: $8.61 to $9.13
• 50-Day Range: $7.47 to $9.07
• 52-Week Range: $5.20 to $10.67
• Volume: 2.01 million shs
• Average Volume: 1.41 million shs
• Market Capitalization: $1.17 billion
• P/E Ratio: 30.82
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Buy

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

Aurinia Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 371st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 409.09%

Earnings Growth

Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aurinia Pharmaceuticals is 30.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aurinia Pharmaceuticals is 30.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.04.

Price to Book Value per Share Ratio

Aurinia Pharmaceuticals has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.39% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently decreased by 4.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aurinia Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aurinia Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.39% of the float of Aurinia Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Aurinia Pharmaceuticals has recently decreased by 4.84%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.81

News Sentiment

Aurinia Pharmaceuticals has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.

Search Interest

32 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.

MarketBeat Follows

4 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

AUPH Stock Analysis - Frequently Asked Questions

How have AUPH shares performed this year?

Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH shares have decreased by 3.9% and is now trading at $8.63.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.08 by $0.08. The biotechnology company earned $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 14.27% and a net margin of 16.11%.
Read the conference call transcript.

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' top institutional investors include Public Employees Retirement System of Ohio (0.02%), Acropolis Investment Management LLC (0.02%), City Center Advisors LLC (0.02%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AUPH
• CIK: 1600620
• Web: www.auriniapharma.com
• Phone: 250-708-4272
• Fax: 250-744-2498
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aurinia Pharmaceuticals: $11.50
• High Price Target: $13.00
• Low Price Target: $10.00
• Potential Upside/Downside: +31.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.28
• Trailing P/E Ratio: 31.20
• Forward P/E Ratio: 79.70
• P/E Growth: N/A
• Net Income: $5.75 million
• Net Margins: 16.11%
• Pretax Margin: 16.91%
• Return on Equity: 14.27%
• Return on Assets: 9.93%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 5.93
• Quick Ratio: 5.26

Sales & Book Value

• Annual Sales: $235.13 million
• Price / Sales: 5.04
• Cash Flow: $0.31 per share
• Price / Cash Flow: 28.69
• Book Value: $2.68 per share
• Price / Book: 3.27

Miscellaneous

• Outstanding Shares: 135,100,000
• Free Float: 118,621,000
• Market Cap: $1.18 billion
• Optionable: Optionable
• Beta: 1.16